This 12-week, unmasked, non-randomized study of three serial 1.9 mg subconjunctival doses of Palomid 529 in neovascular AMD participants who have not responded to conventional anti-VEGF treatments has completed the study objectives. The protocol has been terminated and the results have been published. The study drug was well tolerated and formed a depot at the site of injection. There were no ocular or sytemic toxicity concerns. Although this study was not designed to determine efficacy, there appeared to be no clinical benefit in terms of visual acuity or reduction in macular fluid in our small, short-term study of five participants.
|Nicholson, Benjamin; Noble, Jason; Forooghian, Farzin et al. (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103-26|
|Ardeljan, Daniel; Meyerle, Catherine B; Agron, Elvira et al. (2013) Influence of TIMP3/SYN3 polymorphisms on the phenotypic presentation of age-related macular degeneration. Eur J Hum Genet :|
|Dalal, Monica; Jacobs-El, Naima; Nicholson, Benjamin et al. (2013) Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:2705-9|